In this April 2024 feature for The Bluntness, Scott Mazza, co-founder and COO of Vitality CBD, explains the role cannabinoids play within the entourage effect, alongside terpenes and flavonoids. The article outlines how different cannabinoids, ranging from THC and CBD to lesser-known compounds like CBG and CBN, interact with the endocannabinoid system and with each other to shape therapeutic and experiential outcomes. Citing emerging research and a 2022 clinical trial, Mazza highlights why full-spectrum CBD products may deliver effects at lower doses, reinforcing the importance of compound synergy, product composition, and informed consumer experimentation.

In this April 2024 analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging research comparing CBD and THC for anxiety management. Drawing on a four-week study of 300 participants published in Cannabis and Cannabinoid Research, the article reports that CBD-dominant formulations produced the most consistent anxiety reduction with fewer cognitive side effects than THC-dominant products. Mazza underscores the importance of dosing, product quality, and third-party testing, positioning CBD as a well-tolerated, evidence-supported option while emphasizing the need for continued clinical research.

In this article, Scott Mazza reviews emerging scientific evidence that begins to establish evidence-based daily intake limits for CBD, addressing a long-standing gap in consumer safety guidance. Drawing on a 2023 toxicological review and recent clinical findings, the article outlines proposed upper limits for different adult populations, including stricter thresholds for pregnancy, lactation, and liver risk. Mazza frames these dosage benchmarks as a critical step toward clearer labeling, improved regulatory decision-making, and a more mature, science-led CBD industry.

In this guest column, Scott Mazza examines emerging peer-reviewed research supporting the cannabis “entourage effect,” arguing that cannabinoids, terpenes, and flavonoids interact synergistically to influence therapeutic outcomes beyond isolated compounds alone. Citing findings published in Molecules, the article explains how these interactions may shape analgesic, anti-inflammatory, and neuroprotective effects, while also highlighting the need for further research to clarify compound-specific contributions. Mazza situates these findings within a broader shift toward whole-plant and chemistry-driven approaches to cannabis formulation, treatment, and classification.

Scott Mazza examines the hemp industry’s leading regulatory priorities ahead of the upcoming Farm Bill, including classifying CBD as a conventional dietary supplement and food ingredient, easing testing bottlenecks, and adjusting federal THC limits for hemp. Drawing on current FDA, USDA, and industry positions, the article argues that existing regulatory frameworks can address safety and quality concerns without creating new, uncertain pathways. The piece frames these proposals as pragmatic, farmer-focused adjustments aimed at stabilizing the CBD market and providing clearer federal guidance.

In this article, Scott Mazza of Vitality CBD examines the role of flavonoids in shaping cannabis color, flavor, and aroma, alongside their lesser-known biological functions within the plant. The article explains how flavonoids interact with terpenes and cannabinoids as part of the entourage effect, potentially influencing therapeutic outcomes, particularly in full-spectrum formulations. Mazza also emphasizes the need for deeper research and informed consumer scrutiny, especially regarding product composition, testing standards, and claims around anxiety and other health applications.

In a guest column for NY Cannabis Insider, Scott Mazza explains how the one-year extension of the 2018 Farm Bill delays long-awaited clarity on CBD regulation and hemp-derived cannabinoids, including delta-8 THC, prolonging uncertainty for producers, consumers, and regulators. He outlines how the extension constrains industry planning and innovation while urging producers to rely on third-party testing, transparent labeling, and compliance with existing hemp thresholds to protect consumers during the interim. Mazza argues that clearer federal definitions and enforceable standards in Farm Bill 2024 are essential to stabilize the market, address emerging cannabinoid loopholes, and align regulation with growing scientific evidence and public acceptance.

In a commentary for Nutritional Outlook, Scott Mazza reviews 2023 as a year of regulatory stagnation but meaningful scientific and social progress for CBD, highlighting the delayed Farm Bill update, ongoing uncertainty around delta-8 THC, and FDA hesitation on CBD as a dietary supplement. He outlines key research milestones from the year, including emerging evidence on CBD’s role in opioid use disorder, dosage safety thresholds, hair loss, and other health conditions that continue to reshape the compound’s scientific credibility. Mazza concludes that declining social stigma and growing consumer adoption position CBD for further maturation in 2024, provided policymakers deliver clearer regulatory guidance and enforceable production standards.

In an article for NutraIngredients, Scott Mazza comments on the one-year extension of the 2018 Farm Bill, warning that the delay prolongs regulatory uncertainty around CBD and hemp-derived cannabinoids in the U.S. market. He explains that postponing Farm Bill reform leaves unresolved issues such as the legality of delta-8 THC, complicates long-term planning for producers, and slows innovation across the hemp industry. Mazza argues that clearer federal guidance is urgently needed to provide stability, protect consumers, and support sustainable growth while policymakers continue to debate the future regulatory framework.

In a guest column for NY Cannabis Insider, Scott Mazza analyzes new toxicology research that establishes evidence-based upper limits for daily CBD intake, moving the industry beyond informal dosage “guesstimates.” He highlights findings indicating that healthy adults can safely consume up to 160 mg of CBD per day, while lower limits apply to pregnant or breastfeeding individuals and those at risk of liver injury. Mazza argues that clearly defined dosage thresholds are a necessary step toward responsible regulation, informed consumer use, and the integration of CBD into mainstream health and wellness frameworks.

In a guest column for NY Cannabis Insider, Scott Mazza reviews emerging clinical evidence linking cannabis-based therapies to symptom relief in fibromyalgia, a chronic condition affecting millions of Americans with limited treatment options. He cites recent studies showing that THC- and cannabinoid-containing formulations were associated with statistically significant improvements in pain, depression, and quality of life, as well as reduced reliance on conventional medications. Mazza emphasizes that realizing this therapeutic potential will require more rigorous research alongside stricter industry standards for cannabinoid product purity, potency, and consistency to support medical use.

In an article for Nutritional Outlook, Scott Mazza examines emerging research suggesting that topical hemp formulations rich in cannabinoids, including CBD, may support hair regrowth and could offer an alternative or complement to conventional treatments like finasteride and minoxidil. He highlights findings from a small clinical case series reporting significant hair regrowth without adverse effects, while emphasizing that the mechanism of action appears distinct from existing therapies. Mazza cautions that meaningful progress in CBD-based hair health depends on stronger industry-wide standards for purity, potency, and labeling to ensure consumer safety and scientific credibility.